Nu Skin Enterprises (NUS)
(Delayed Data from NYSE)
$10.75 USD
+0.03 (0.28%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $10.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$10.75 USD
+0.03 (0.28%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $10.75 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value D Growth F Momentum B VGM
Zacks News
Helen of Troy (HELE) Surpasses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Helen of Troy (HELE) delivered earnings and revenue surprises of 24.23% and 8.27%, respectively, for the quarter ended May 2022. Do the numbers hold clues to what lies ahead for the stock?
Nu Skin (NUS) Down More Than 10% in 6 Months: Here's Why
by Zacks Equity Research
Nu Skin (NUS) has been grappling with global uncertainties like rising pandemic-related factors, unfavorable currency rates and geopolitical conflicts.
Nu Skin (NUS) Up 8.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin (NUS) Looks Troubled on Volatile Currency Movements
by Zacks Equity Research
Nu Skin Enterprises (NUS) has been encountering global uncertainties like rising pandemic-related factors, unfavorable currency rates and geopolitical conflicts.
Nu Skin Enterprises (NUS) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 4.11% and 4.48%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Estee Lauder (EL) Q3 Earnings Surpass Estimates
by Zacks Equity Research
Estee Lauder (EL) delivered earnings and revenue surprises of 14.46% and 1.81%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Inter Parfums' (IPAR) Alliances To Put Stock On Growth Trajectory
by Zacks Equity Research
Inter Parfums (IPAR) is on track to expand its business through new licenses or acquisitions. Also, the company's product launches keep it well placed.
Is Nu Skin Enterprises (NUS) a Great Value Stock Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Coty (COTY) Up More Than 10% in 6 Months: More Room for Growth?
by Zacks Equity Research
Coty (COTY) has been gaining from its six core priorities and prudent alliances. The company's solid products and brands have been aiding, while cost inflation and supply-chain woes hurt.
Nu Skin (NUS) Up More Than 15% in 6 Months: Here's Why
by Zacks Equity Research
Nu Skin (NUS) is benefiting from technological advancements and strategic product programs. Management is optimistic about its Nu Vision 2025 strategy.
Kimberly-Clark (KMB) Faces High Costs, Down Over 10% in 3 Months
by Zacks Equity Research
Kimberly-Clark (KMB) is battling high input costs for the past few quarters. Soft sales in the company's Consumer Tissue segment are also a concern.
Philip Morris (PM) Takes Bold Steps to Cut Operations in Russia
by Zacks Equity Research
Philip Morris (PM) discontinues several cigarette products it offered Russia. It has also canceled all product launches, which were planned for 2022, in Russia among other steps.
Why Nu Skin Enterprises (NUS) is a Top Growth Stock for the Long-Term
by Zacks Equity Research
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Nu Skin (NUS) Down 15.3% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Nu Skin (NUS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Nu Skin's (NUS) Effective Growth Efforts & Product Launches Aid
by Zacks Equity Research
Nu Skin (NUS) is optimistic about its Nu Vision 2025 strategy to become the world's leading integrated beauty and wellness company, driven by a dynamic affiliate opportunity platform.
McCormick (MKC) Suspends Russian Operations Amid Conflict
by Zacks Equity Research
McCormick (MKC) suspends operations in Russia after stopping advertising and promotional activity as well as other investments in the country.
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Nu Skin (NUS) Q4 Earnings Beat Estimates, Revenues Down
by Zacks Equity Research
Nu Skin's (NUS) fourth-quarter 2021 earnings and revenues decline year over year. Management offers a drab view for the first quarter.
Nu Skin Enterprises (NUS) Q4 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Nu Skin (NUS) delivered earnings and revenue surprises of 16.84% and 2.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Nu Skin Enterprises (NUS) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Nu Skin (NUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Nu Skin (NUS) Shines on Solid Sales Leaders & Customer Network
by Zacks Equity Research
Nu Skin Enterprises (NUS) has been benefiting from its efforts to empower sales leaders and strengthen the customer base.
Inter Parfums (IPAR) Up More Than 40% in 6 Months: Here's Why
by Zacks Equity Research
Inter Parfums (IPAR) is benefiting from its focus on business expansion through new licenses. The company is also on track with effective product launches.
Coty (COTY) Gains on Strategic Pillars & Solid Brand Portfolio
by Zacks Equity Research
Coty (COTY) has been benefiting from its six strategic pillars. Solid e-commerce performance and gains from alliances and agreements have been working well for the company.
Is Nu Skin Enterprises (NUS) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Helen of Troy (HELE) Poised on Leadership Brands, Strategies
by Zacks Equity Research
Helen of Troy (HELE) is focused on making investments in its Leadership Brands. Management is progressing well with key growth areas under its Phase II Transformation efforts.